CN107406500B - 抗甲状腺素运载蛋白抗体 - Google Patents

抗甲状腺素运载蛋白抗体 Download PDF

Info

Publication number
CN107406500B
CN107406500B CN201680015343.2A CN201680015343A CN107406500B CN 107406500 B CN107406500 B CN 107406500B CN 201680015343 A CN201680015343 A CN 201680015343A CN 107406500 B CN107406500 B CN 107406500B
Authority
CN
China
Prior art keywords
seq
antibody
cdr
ttr
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680015343.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107406500A (zh
Inventor
A·恰克拉布阿缇
塔洛陈·S.·尼扎
J·N·海加凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neoto Neuroscience Ltd
University Health Network
Novo Nordisk AS
Original Assignee
University Health Network
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network, Prothena Biosciences Ltd filed Critical University Health Network
Publication of CN107406500A publication Critical patent/CN107406500A/zh
Application granted granted Critical
Publication of CN107406500B publication Critical patent/CN107406500B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680015343.2A 2015-01-28 2016-01-28 抗甲状腺素运载蛋白抗体 Active CN107406500B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562109004P 2015-01-28 2015-01-28
US62/109,004 2015-01-28
US201562266555P 2015-12-11 2015-12-11
US62/266,555 2015-12-11
PCT/IB2016/050416 WO2016120811A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (2)

Publication Number Publication Date
CN107406500A CN107406500A (zh) 2017-11-28
CN107406500B true CN107406500B (zh) 2022-02-25

Family

ID=55300737

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680015343.2A Active CN107406500B (zh) 2015-01-28 2016-01-28 抗甲状腺素运载蛋白抗体

Country Status (25)

Country Link
US (1) US20160257737A1 (enExample)
EP (1) EP3250593B1 (enExample)
JP (1) JP7101927B2 (enExample)
KR (1) KR102649788B1 (enExample)
CN (1) CN107406500B (enExample)
AU (1) AU2016210889C1 (enExample)
CA (1) CA2974993A1 (enExample)
CO (1) CO2017008482A2 (enExample)
CU (1) CU20170098A7 (enExample)
DK (1) DK3250593T3 (enExample)
EA (1) EA036014B1 (enExample)
ES (1) ES2925716T3 (enExample)
HR (1) HRP20220918T1 (enExample)
HU (1) HUE059592T2 (enExample)
MX (1) MX389911B (enExample)
MY (1) MY193701A (enExample)
PE (1) PE20180218A1 (enExample)
PL (1) PL3250593T3 (enExample)
PT (1) PT3250593T (enExample)
RS (1) RS63513B1 (enExample)
SA (1) SA517381981B1 (enExample)
SG (2) SG11201706126WA (enExample)
SI (1) SI3250593T1 (enExample)
TW (2) TWI769570B (enExample)
WO (1) WO2016120811A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A2 (en) * 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2019070901A1 (en) 2017-10-04 2019-04-11 Amgen Inc. IMMUNOGLOBULIN FUSIONS OF TRANSTHYRETIN
WO2019071205A1 (en) * 2017-10-06 2019-04-11 Prothena Biosciences Limited ANTI-TRANSTHYRETIN ANTIBODY
CN111757730A (zh) 2017-10-06 2020-10-09 普罗塞纳生物科学有限公司 检测甲状腺素运载蛋白的方法
BR112020010483A2 (pt) * 2017-11-29 2020-10-20 Prothena Biosciences Limited formulação liofilizada de um anticorpo monoclonal contra transtirretina
WO2020003172A1 (en) 2018-06-26 2020-01-02 Mor Research Applications Transthyretin antibodies and uses thereof
CN111018976B (zh) * 2018-10-10 2022-04-01 东莞市朋志生物科技有限公司 一种抗人心肌肌钙蛋白i的重组抗体
ES2989499T3 (es) * 2018-11-09 2024-11-26 Neurimmune Ag Modelo de roedor de xenoinjerto de amiloide derivado de paciente
CN116751295A (zh) * 2019-06-04 2023-09-15 江苏恒瑞医药股份有限公司 能结合胸腺基质淋巴细胞生成素的抗体及其应用
CA3140208A1 (en) * 2019-07-08 2021-01-14 Amgen Inc. Multispecific transthyretin immunoglobulin fusions
US20230235048A1 (en) 2020-06-24 2023-07-27 Andriani IOANNOU Antibodies recognizing sortilin
CN118059229A (zh) * 2020-10-14 2024-05-24 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
CA3200767A1 (en) * 2020-12-03 2022-06-09 Zhiwan WANG Anti-tslp antibody pharmaceutical composition and use thereof
CN117603360A (zh) * 2020-12-16 2024-02-27 美勒斯公司 用于治疗癌症的多特异性抗体
CN117916599A (zh) 2021-09-07 2024-04-19 美国西门子医学诊断股份有限公司 生物标记物组合物及其使用方法
CN116804186B (zh) * 2023-07-05 2023-12-22 中国兽医药品监察所 一种抗鸡传染性贫血病毒单克隆抗体杂交瘤细胞株、单克隆抗体、试剂或试剂盒及其应用
WO2025125544A1 (en) 2023-12-15 2025-06-19 Novo Nordisk A/S Stable liquid formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2010195710A (ja) * 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用
CA2886254A1 (en) * 2012-10-08 2014-04-17 Prothena Biosciences Limited Antibodies recognizing alpha-synuclein

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE490518T1 (de) 1999-02-05 2010-12-15 Samsung Electronics Co Ltd Verfahren und vorrichtung zum wiederauffinden von texturbildern
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
ES2293096T3 (es) 2002-11-29 2008-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
JP4620739B2 (ja) 2004-11-10 2011-01-26 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｃｈｏ細胞に対する細胞保存戦略を最適化するためのフローサイトメトリ分析の使用
WO2007124345A2 (en) 2006-04-21 2007-11-01 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
CA2699837C (en) 2006-12-01 2017-06-13 Seattle Genetics, Inc. Variant target binding agents and uses thereof
JP5467415B2 (ja) 2007-03-02 2014-04-09 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト タンパク質製造の改良
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
US9790269B2 (en) * 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
EP3022225B1 (en) * 2013-07-19 2021-09-29 Board Of Regents Of the University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2010195710A (ja) * 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用
CA2886254A1 (en) * 2012-10-08 2014-04-17 Prothena Biosciences Limited Antibodies recognizing alpha-synuclein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Transthyretin Aggregate-Specific Antibodies Recognize Cryptic Epitopes on Patient-Derived Amyloid Fibrils";Monichan Phay等;《REJUVENATION RESEARCH》;20141231;第17卷(第2期);第97-104页 *

Also Published As

Publication number Publication date
MX2017009803A (es) 2018-08-15
SG10201906696RA (en) 2019-08-27
AU2016210889C1 (en) 2022-02-10
CO2017008482A2 (es) 2018-01-16
EA201791710A1 (ru) 2017-12-29
AU2016210889A1 (en) 2017-08-10
HUE059592T2 (hu) 2022-11-28
ES2925716T3 (es) 2022-10-19
KR20170120608A (ko) 2017-10-31
KR102649788B1 (ko) 2024-03-20
MX389911B (es) 2025-03-04
CA2974993A1 (en) 2016-08-04
AU2016210889B2 (en) 2021-10-21
EA036014B1 (ru) 2020-09-14
US20160257737A1 (en) 2016-09-08
CN107406500A (zh) 2017-11-28
WO2016120811A1 (en) 2016-08-04
SI3250593T1 (sl) 2022-09-30
RS63513B1 (sr) 2022-09-30
EP3250593B1 (en) 2022-06-22
SG11201706126WA (en) 2017-08-30
TW202110896A (zh) 2021-03-16
TWI769570B (zh) 2022-07-01
BR112017016345A2 (pt) 2018-03-27
DK3250593T3 (da) 2022-08-22
JP2018510617A (ja) 2018-04-19
SA517381981B1 (ar) 2022-05-17
PE20180218A1 (es) 2018-01-31
JP7101927B2 (ja) 2022-07-19
CU20170098A7 (es) 2018-03-13
PL3250593T3 (pl) 2022-09-19
HRP20220918T1 (hr) 2022-10-28
MY193701A (en) 2022-10-25
TWI711631B (zh) 2020-12-01
TW201636371A (zh) 2016-10-16
PT3250593T (pt) 2022-08-31
EP3250593A1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
CN107406500B (zh) 抗甲状腺素运载蛋白抗体
CN107406499B (zh) 抗甲状腺素运载蛋白抗体
CN107428822B (zh) 抗甲状腺素运载蛋白抗体
CN111315213B (zh) 抗甲状腺素运载蛋白抗体
AU2018345807B2 (en) Methods of detecting transthyretin
CN109415432B (zh) Tau免疫疗法
KR20150129736A (ko) Tau 면역치료제
JP2019530427A (ja) 抗トランスサイレチン抗体
JP2019530428A (ja) 抗トランスサイレチン抗体
JP2019532617A (ja) 抗トランスサイレチン抗体
US10633433B2 (en) Anti-transthyretin antibodies
KR20160131082A (ko) Lg1-3에 특이적인 항-라미닌4 항체
HK1240247B (en) Anti‐transthyretin antibodies
HK1240247A1 (en) Anti‐transthyretin antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240126

Address after: Baggswald, Denmark

Patentee after: NOVO NORDISK A/S

Country or region after: Denmark

Patentee after: University HEALTH NETWORK

Country or region after: Canada

Address before: Ai Erlandubailin

Patentee before: Neoto Neuroscience Ltd.

Country or region before: Ireland

Patentee before: University HEALTH NETWORK

Country or region before: Canada

Effective date of registration: 20240126

Address after: Ai Erlandubailin

Patentee after: Neoto Neuroscience Ltd.

Country or region after: Ireland

Patentee after: University HEALTH NETWORK

Country or region after: Canada

Address before: Ai Erlandubailin

Patentee before: PROTHENA BIOSCIENCES Ltd.

Country or region before: Ireland

Patentee before: University HEALTH NETWORK

Country or region before: Canada

TG01 Patent term adjustment
TG01 Patent term adjustment